Bing Yao

Dr. Zheng Bin Yao is an Independent Director at Alumis, Inc. and a Chairman & Chief Executive Officer at Arrivent BioPharma, Inc. He is on the Board of Directors at Alumis, Inc., Immune-Onc Therapeutics, Inc. and NiKang Therapeutics, Inc. Dr. Yao was previously employed as an Independent Non-Executive Director by VISEN Pharmaceuticals, a Chairman, President & Chief Executive Officer by Viela Bio, Inc., an Independent Director by NexImmune, Inc., a Senior Vice President & Head-Immuno-Oncology by MedImmune LLC, a Vice President & Head-Research by Tanox, Inc., a Head-Immuno-Oncology Franchise by AstraZeneca PLC, and a Head-Immunology & Infectious Diseases by Genentech, Inc. He received his graduate degree from Anhui Medical University and a doctorate degree from the University of Iowa.